Incorporating Long-Acting Insulin Glargine Into the UVA/Padova Type 1 Diabetes Simulator for In Silico Testing of MDI Therapies
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Glargine 100 U/mL (Gla-100) and 300 U/mL (Gla-300) are long-acting insulin analogs providing basal insulin supply in multiple daily injection (MDI) therapy of type 1 diabetes (T1D). Both insulins require extensive testing to arrive at the optimal dosing regimen, e.g., timing and amount. Here we aim at a simulation tool for evaluating benefits/risks of different dosing schemes and up-titration rules for both Gla-100 and Gla-300 before clinical testing. METHODS: A new pharmacokinetic (PK) model of both Gla-100 and Gla-300 was incorporated into the FDA-accepted University of Virginia/Padova T1D simulator: Specifically, a joint parameter distribution, built from PK parameter estimates, was used to generate individual PK parametrizations for each in silico subject. A virtual trial comparing Gla-100 vs. Gla-300 was performed and assessed against a clinical study to validate the glargine simulator. RESULTS: Like in vivo, in silico both insulins performed similarly with respect to glucose control: percent time of glucose between [80-140] mg/dL with Gla-100 vs. Gla-300 (primary endpoint) were 41.5 ± 1.1% vs. 39.0 ± 1.2% (P = 0.11) in silico, 31.0 ± 1.6% vs. 31.8 ± 1.5% (P = 0.73) in vivo. CONCLUSIONS: The glargine simulator reproduced the main findings of the clinical trial, proving its validity for testing MDI therapies. SIGNIFICANCE: In silico testing of MDI therapies can help designing clinical trials. Due to the more standardized settings in silico (e.g., standardized meals and strict adherence to titration rule), any potential treatment effect is reaching statistical significance in simulation vs. clinical trial.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“models of acetaminophen pharmacokinetic and long-acting insulin were introduced; [74][75][76]”
From Developing the UVA/Padova Type 1 Diabetes Simulator: Modeling, Validation, Refinements, and Utility (2023) · cites this paper as [76]
Citations
Cites
Meal Simulation Model of the Glucose-Insulin System
Dalla Man, C., Rizza, R. A., & Cobelli, C. (2007) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2007.893506 · Cited by 955 · cited 2×
“048L/kg) and second we reparameterized the model so that m2 , m3 , m4 become function of m1 , the plasma insulin clearance (CL, L/min) and VI , according to what was done in [10].”
MethodSelf-citationBecker, R. H. A., Dahmen, R., Bergmann, K., Lehmann, A., Jax, T., & Heise, T. (2015) · Diabetes Care · doi:10.2337/dc14-0006 · Cited by 407 · cited 3×
“We refer to [7], [8],”
MethodResultKovatchev, B. P., Cox, D. J., Gonder-Frederick, L. A., Young-Hyman, D., Schlundt, D., & Clarke, W. (1998) · Diabetes Care · doi:10.2337/diacare.21.11.1870 · Cited by 310 · cited 1×
“Gla-100 in terms of percent time in target 70–180 mg/dL (Tt), tight target 80–140 mg/dL, (Ttt), below 70 mg/dL (Tb), above 180 mg/dL (Ta), BG mean (MBG) and standard deviation (SD), low and high BG indexes (LBGI, HBGI) [24], [25], and hourly risk range (HRR) [26].”
BackgroundThe UVA/Padova Type 1 Diabetes Simulator Goes From Single Meal to Single Day
Visentin, R., Campos-Náñez, E., Schiavon, M., Lv, D., Vettoretti, M., Breton, M., Kovatchev, B. P., Dalla Man, C., & Cobelli, C. (2018) · Journal of Diabetes Science and Technology · doi:10.1177/1932296818757747 · Cited by 280
Self-citationMetrics for glycaemic control - from HbA1c to continuous glucose monitoring
Kovatchev, B. P. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.3 · Cited by 272
Carbohydrate counting accuracy and blood glucose variability in adults with type 1 diabetes
Brazeau, A. S., Mircescu, H., Desjardins, K., Leroux, C., Strychar, I., Ekoé, J. M., & Rabasa-Lhoret, R. (2013) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.10.024 · Cited by 265 · cited 1×
“, timing and amount, were generated as reported in [14], mimicking the habits occurring in real life: three meals per day were randomly generated for each subject assuming mealtime uniformly distributed in the intervals 06:30 am–08:00 am (breakfast), 11:30 am–01:00 pm (lunch), 06:30 pm–08:00 pm (dinner); meal amounts…”
MethodHome, P. D., Bergenstal, R. M., Bolli, G. B., Ziemen, M., Rojeski, M., Espinasse, M., & Riddle, M. C. (2015) · Diabetes Care · doi:10.2337/dc15-0249 · Cited by 221 · cited 1×
“19 U/kg [23].”
A minimal model of insulin secretion and kinetics to assess hepatic insulin extraction
Toffolo, G., Campioni, M., Basu, R., Rizza, R. A., & Cobelli, C. (2006) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00473.2004 · Cited by 142
Self-citationLow within‐ and between‐day variability in exposure to new insulin glargine 300 U/ml
Becker, R. H. A., NOWOTNY, I. K., Teichert, L., Bergmann, K., & Kapitza, C. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12416 · Cited by 133 · cited 1×
“respectively, as reported in [22].”
Toward a Run-to-Run Adaptive Artificial Pancreas: In Silico Results
Toffanin, C., VISENTIN, R., Messori, M., Palma, F. D., Magni, L., & Cobelli, C. (2017) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2017.2652062 · Cited by 123 · cited 1×
“sensitivity [15] and the dawn phenomenon [16], which extended the domain of validity of the simulator from single- to multiplemeal scenarios.”
BackgroundSelf-citationBergenstal, R. M., Bailey, T. S., Rodbard, D., Ziemen, M., Guo, H., Muehlen-Bartmer, I., & Ahmann, A. (2017) · Diabetes Care · doi:10.2337/dc16-0684 · Cited by 123 · cited 9×
“the findings of a clinical trial evaluating both treatments using continuous glucose monitoring [6].”
BackgroundMethodResultInfluentialVettoretti, M., Facchinetti, A., Sparacino, G., & Cobelli, C. (2017) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2017.2746340 · Cited by 120
Self-citationCircadian Variability of Insulin Sensitivity: Physiological Input for In Silico Artificial Pancreas
Visentin, R., Dalla Man, C., Kudva, Y. C., Basu, A., & Cobelli, C. (2015) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2014.0192 · Cited by 113 · cited 1×
“sensitivity [15] and the dawn phenomenon [16], which extended the domain of validity of the simulator from single- to multiplemeal scenarios.”
BackgroundSelf-citationShiramoto, M., Eto, T., Irie, S., Fukuzaki, A., Teichert, L., Tillner, J., Takahashi, Y., Koyama, M., Dahmen, R., Heise, T., et al. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12415 · Cited by 107 · cited 3×
“We refer to [7], [8],”
MethodResultVisentin, R., Dalla Man, C., Kovatchev, B., & Cobelli, C. (2014) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2013.0377 · Cited by 103
Self-citationThe kinetics of insulin in man. I. General aspects
Ferrannini, E., & Cobelli, C. (1987) · Diabetes/Metabolism Reviews · doi:10.1002/dmr.5610030201 · Cited by 99 · cited 1×
“The glargine PKmodel has been identified on data [7], [8], [9], assuming a two-compartment model structure, [18], as shown in (2) at the bottom of this page, where Ip and Il (mU/kg) are the mass of insulin in plasma and liver, respectively, I (μU/mL) plasma insulin concentration, suffix b denotes basal state, m1 ,”
MethodSelf-citationBailey, T. S., Pettus, J., Roussel, R., Schmider, W., Maroccia, M., Nassr, N., Klein, O., Bolli, G. B., & Dahmen, R. (2018) · Diabetes & Metabolism · doi:10.1016/j.diabet.2017.10.001 · Cited by 94 · cited 3×
“[9] for more details on protocol and experimental procedures.”
BackgroundMethodResultKovatchev, B. P., Cox, D. J., Gonder-Frederick, L. A., & Clarke, W. L. (2002) · Diabetes Technology & Therapeutics · doi:10.1089/152091502760098438 · Cited by 86 · cited 1×
“Gla-100 in terms of percent time in target 70–180 mg/dL (Tt), tight target 80–140 mg/dL, (Ttt), below 70 mg/dL (Tb), above 180 mg/dL (Ta), BG mean (MBG) and standard deviation (SD), low and high BG indexes (LBGI, HBGI) [24], [25], and hourly risk range (HRR) [26].”
BackgroundVisentin, R., Man, C. D., & Cobelli, C. (2016) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2016.2535241 · Cited by 86 · cited 3×
“, timing and amount, were generated as reported in [14], mimicking the habits occurring in real life: three meals per day were randomly generated for each subject assuming mealtime uniformly distributed in the intervals 06:30 am–08:00 am (breakfast), 11:30 am–01:00 pm (lunch), 06:30 pm–08:00 pm (dinner); meal amounts…”
MethodSelf-citationModeling Subcutaneous Absorption of Fast-Acting Insulin in Type 1 Diabetes
Schiavon, M., Dalla Man, C., & Cobelli, C. (2018) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2017.2784101 · Cited by 54 · cited 1×
“In addition, the simulator already incorporates a model of sc fast-acting insulin administration [17].”
MethodSelf-citationRegulation Catches Up to Reality: Nonadjunctive Use of Continuous Glucose Monitoring Data
Edelman, S. V. (2017) · Journal of Diabetes Science and Technology · doi:10.1177/1932296816667749 · Cited by 51 · cited 1×
“This tool was initially created to test in silico artificial pancreas control algorithms and, recently, it was also used to explore different titration rules and dosing regimens of an inhalable ultra-fast acting insulin [3], and to test non-adjunctive use of continuous glucose monitoring (CGM) [4].”
MethodVisentin, R., Giegerich, C., Jäger, R., Dahmen, R., Boss, A., Grant, M., Dalla Man, C., Cobelli, C., & Klabunde, T. (2016) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0128 · Cited by 36
Self-citationHu, R., & Li, C. (2015) · Computational and Mathematical Methods in Medicine · doi:10.1155/2015/281589 · Cited by 34 · cited 1×
“in [21].”
Modeling Subcutaneous Absorption of Long-Acting Insulin Glargine in Type 1 Diabetes
Schiavon, M., VISENTIN, R., Giegerich, C., Klabunde, T., Cobelli, C., & Man, C. D. (2019) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2019.2919250 · Cited by 18 · cited 8×
“paper [5]).”
BackgroundMethodResultInfluentialSelf-citationFrias, P. F., & Frías, J. P. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0926-8 · Cited by 15 · cited 1×
“Focusing on basal insulins, long-acting insulin analogs have been developed, like insulin glargine 100 U/mL (Gla-100, Lantus, Sanofi) and detemir (Levemir, Novo Nordisk), and, more recently, glargine 300 U/mL (Gla-300, Toujeo, Sanofi) and degludec (Tresiba, Novo Nordisk), aiming to mimic a constant insulin profile [1].”
Background
Cited by
Mehmood, S., Ahmad, I., Arif, H., Ammara, U. E., & Majeed, A. (2020) · Applied System Innovation · doi:10.3390/asi3030031 · Cited by 58
Developing the UVA/Padova Type 1 Diabetes Simulator: Modeling, Validation, Refinements, and Utility
Cobelli, C., & Kovatchev, B. (2023) · Journal of Diabetes Science and Technology · doi:10.1177/19322968231195081 · Cited by 46
“…extended beyond its initial single-meal realm of application; 73 models of acetaminophen pharmacokinetic and long-acting insulin were introduced; 74-76 the intraperitoneal (IP) absorption of insulin was modeled; 77,78 and replay simulation and insulin sensitivity assessment techniques were…”
MethodSelf-citationVISENTIN, R., Cobelli, C., & Man, C. D. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0110 · Cited by 44
Self-citationMughal, I. S., Patané, L., & Caponetto, R. (2024) · Annual Reviews in Control · doi:10.1016/j.arcontrol.2024.100937 · Cited by 46
Fathi, A. E., Kearney, R. E., Palisaitis, E., Boulet, B., & Haidar, A. (2020) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2020.3023555 · Cited by 25
“Models describing the pharmacokinetics of long-acting insulins exist in the literature [25], [26].”
Background
Metadata
- Authors
- Visentin, R., Schiavon, M., Giegerich, C., Klabunde, T., Man, C. D., & Cobelli, C.
- Affiliations
- University of Padua (IT)
- Sanofi (Germany) (DE)
- ORCID
- Venue
- IEEE Transactions on Biomedical Engineering
- Published
- 2019-10
- Volume
- 66
- Issue
- 10
- Pages
- 2889-2896
- ISSN
- 0018-9294 (ISSN-L)
- 1558-2531
- OpenAlex
- W2913964535
- Cited by
- 22
- References
- 25
- Citations by year
- 2025: 3 · 2024: 5 · 2023: 2 · 2022: 2 · 2021: 3 · 2020: 6 · 2019: 1
- FWCI
- 2.44
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- IEEE Transactions on Biomedical Engineering (publishedVersion)
- PubMed (publishedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- Sanofi
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Keywords
- long-acting insulin, insulin glargine, type 1 diabetes, UVA/Padova simulator, pharmacokinetic modeling, insulin dosing regimens, glycemic control
- MeSH terms
- Insulin Glargine, Blood Glucose, Computer Simulation, Diabetes Mellitus, Type 1, Drug Administration Schedule, Humans, Hypoglycemic Agents, Injections, Insulin, Long-Acting
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.